Cargando…

BRAF inhibition generates a host/tumor niche that mediates therapeutic escape

The current study defines a fibroblast-derived niche that facilitates the therapeutic escape of melanoma cells from BRAF inhibition. Vemurafenib treatment led to the release of TGF-β from the melanoma cells that increased the differentiation state of the fibroblasts; an affect associated with fibron...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fedorenko, Inna V., Wargo, Jennifer A., Flaherty, Keith T., Messina, Jane L., Smalley, Keiran S.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648653/ https://www.ncbi.nlm.nih.gov/pubmed/26302068 http://dx.doi.org/10.1038/jid.2015.329

Ejemplares similares

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

The complexity of microenvironment-mediated drug resistance
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
por: Paraiso, K H T, et al.
Publicado: (2010)

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition
por: Phadke, Manali, et al.
Publicado: (2017)

Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma
por: Smalley, Inna, et al.
Publicado: (2019)

HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
por: Sriramareddy, Sathya Neelature, et al.
Publicado: (2022)

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes
por: Cooper, Zachary A, et al.
Publicado: (2013)

Beyond BRAF: where next for melanoma therapy?
por: Fedorenko, I V, et al.
Publicado: (2015)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

Why do women with melanoma do better than men?
por: Smalley, Keiran SM
Publicado: (2018)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
por: Sullivan, Ryan J., et al.
Publicado: (2011)

XL888 limits vemurafenib-induced proliferative skin events by suppressing paradoxical MAPK activation
por: Phadke, Manali, et al.
Publicado: (2015)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF(high)/AXL(low) melanoma
por: Smith, Michael P., et al.
Publicado: (2018)

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
por: Sabbatino, Francesco, et al.
Publicado: (2014)

SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer
por: Li, Jiannong, et al.
Publicado: (2017)

Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
por: Khaliq, Mehwish, et al.
Publicado: (2019)

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition
por: Young, Helen L., et al.
Publicado: (2017)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation
por: John, Jobin K., et al.
Publicado: (2012)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics
por: Frederick, Dennie T., et al.
Publicado: (2014)

Is the Potable Water System an Advantageous Preinfection Niche for Bacteria Colonizing the Cystic Fibrosis Lung?
por: Wargo, Matthew J.
Publicado: (2019)

Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma
por: Koomen, John M., et al.
Publicado: (2011)

Acral melanoma: new insights into the immune and genomic landscape
por: Carvalho, Larissa Anastacio DaCosta, et al.
Publicado: (2023)

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
por: Friedman, Adam A., et al.
Publicado: (2015)

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling
por: Yin, Qing, et al.
Publicado: (2019)

Catch me if you can: how AML and its niche escape immunotherapy
por: Tettamanti, Sarah, et al.
Publicado: (2021)

The Great Escape: Pathogen Versus Host
por: Kong, Eric, et al.
Publicado: (2015)

EGFR blockade prevents glioma escape from BRAF(V600E) targeted therapy
por: Yao, Tsun-Wen, et al.
Publicado: (2015)

Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance
por: Fattore, Luigi, et al.
Publicado: (2022)

Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis
por: Kessler, Brittelle E., et al.
Publicado: (2018)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

MITF Modulates Therapeutic Resistance through EGFR Signaling
por: Ji, Zhenyu, et al.
Publicado: (2015)

23. RETROSPECTIVE REVIEW OF ADULT PATIENTS WITH LEPTOMENINGEAL DISEASE SECONDARY TO MELANOMA AT MOFFITT CANCER CENTER: DIAGNOSIS, TREATMENT AND OUTCOMES
por: Pina, Yolanda, et al.
Publicado: (2020)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
por: Poulikakos, Poulikos I., et al.
Publicado: (2011)

LPTO-03. IN-VITRO & IN-VIVO CULTURE OF PATIENT (PT) DERIVED CSF-CTCs IN LEPTOMENINGEAL DISEASE (LMDz) FROM MELANOMA TO IDENTIFY NOVEL TREATMENT STRATEGIES
por: Law, Vincent, et al.
Publicado: (2019)

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
por: Law, Vincent, et al.
Publicado: (2021)

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation
por: Kim, Hyungsoo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e3k33vmghavmmi1o8cksefaeg9